“Prenatal therapies are the next disruptive technologies in health care, which will advance and shape the future of patient care in the 21st century,” said Graça Almeida-Porada, a professor at the Fetal Research and Therapy Center of the Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina. At the American Society of Gene & Cell Therapy (ASGCT) annual meeting in Baltimore on May 5, 2024, Almeida-Porada introduced the first presentation of the scientific symposium “Prospects for Prenatal Gene and Cell Therapy.”
Prologue Medicines Inc. has launched to develop therapeutics created from the viral proteome, which are proteins produced across all viruses. It’s a newer twist on harnessing the power of the proteins that regulate biology.
Despite what University of Pennsylvania (Penn) immunotherapy pioneer Carl June referred to as a “cold slap last November” – a launched investigation by the U.S. FDA into a possible link between CAR T-cell immunotherapies and secondary cancers – new unpublished studies by Penn and Stanford University highlight the rarity of such cases.
MicroRNAs (miRNAs) are small noncoding RNAs that play important roles in immune response regulation in autoimmune disease such as autoimmune hepatitis. Researchers investigated whether Δ8-tetrahydrocannabinol (THC), which is present in marijuana, could prevent the development of autoimmune hepatitis in treated mice by altering miRNA expression.
Vyne Therapeutics Inc. has received IND clearance from the FDA allowing it to initiate a first-in-human phase Ia study of VYN-202, an oral small-molecule BD2-selective BET inhibitor for autoimmune diseases.
Autoantibodies can promote inflammation and activate complement pathways and immune cell responses causing tissue damage in autoantibody-driven diseases. Researchers from Seismic Therapeutic Inc. have presented data on S-1117.
Boston-based South Korean biotech Genosco Inc. said on April 25 that it passed a technology review required for the special listing track on the tech-heavy Kosdaq market, as it readies an IPO on the Korea Exchange.
Repertoire Immune Medicines Inc. has entered a multiyear strategic collaboration with Bristol Myers Squibb Co. (BMS) to develop tolerizing vaccines for up to three autoimmune diseases.
A week after Bristol Myers Squibb Co. disclosed a significant restructuring plan to focus on long-term growth drivers, the big pharma partnered with Repertoire Immune Medicines Inc. in an early stage, multiyear collaboration to develop T-cell targeted medicines for up to three autoimmune diseases, paying $65 million up front, with a potential $1.8 billion in development, regulatory and commercial milestones, along with tiered royalties.
Boston-based South Korean biotech Genosco Inc. said on April 25 that it passed a technology review required for the special listing track on the tech-heavy Kosdaq market, as it readies an IPO on the Korea Exchange.
RSS
